medigraphic.com
ISSN 2992-7757 (Digital)
Órgano de difusión de la Asociación Latinoamericana de Cirugía y Traumatología Bucomaxilofacial (ALACIBU)

2022, Número 1

<< Anterior Siguiente >>

Lat Am J Oral Maxillofac Surg 2022; 2 (1)


Uso de proteínas morfogenéticas óseas en la reconstrucción de defectos maxilofaciales causados por carcinoma escamoso oral: ¿es seguro su uso?

Solano N, Parra E, Peraza A, Dueñes G

Idioma: Ingles.
Referencias bibliográficas: 58
Paginas: 19-24
Archivo PDF: 219.91 Kb.


RESUMEN

En la región maxilofacial, los grandes defectos que requieren reconstrucciones óseas surgen con mayor frecuencia de la resección del carcinoma oral de células escamosas en estadios avanzados. Las proteínas morfogenéticas óseas humanas (BMP) recientemente han ganado popularidad como un factor de crecimiento potencial para la formación ósea de novo en la reconstrucción debido a su actividad osteoinductora; sin embargo, su uso en pacientes con defectos craneomaxilofaciales después de resecciones de carcinoma de células escamosas oral sigue estando contraindicado debido a la escasez de datos sobre los efectos biológicos de las BMP sobre el cáncer. El propósito de este estudio es examinar el papel de las BMP en la malignidad oral. Según el ligando de BMP y el tipo de cáncer, las BMP pueden promover o inhibir la tumorigénesis. Según los datos recopilados por esta investigación, no recomendamos el uso de BMP para reconstruir los defectos óseos maxilofaciales causados por la resección del carcinoma oral de células escamosas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60 (5): 277-300.

  2. Goldenberg D, Lee J, Koch WM, Kim MM, Trink B, Sidransky D, et al. Habitual risk factors for head and neck cancer. Otolaryngol Head Neck Surg. 2004; 131 (6): 986-993.

  3. Gao Q, Tong W, Luria JS, Wang Z, Nussenbaum B, Krebsbach PH. Effects of bone morphogenetic protein-2 on proliferation and angiogenesis in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2010; 39 (3): 266-271.

  4. Chenard KE, Teven CM, He TC, Reid RR. Bone morphogenetic proteins in craniofacial surgery: current techniques, clinical experiences, and the future of personalized stem cell therapy. J Biomed Biotechnol. 2012; 2012: 601549.

  5. Patel R, McCluskey S, Goldstein D, Minkovich L, Irish J, Brown D, et al. Clinicopathologic and therapeutic risk factors for perioperative complications and prolonged hospital stay in free flap reconstruction of the head and neck. Head Neck. 2010; 32 (10): 1345-1353.

  6. Desai S, Sclaroff A, Nussenbaum B. Use of recombinant human bone morphogenetic protein 2 for mandible reconstruction. JAMA Facial Plast Surg. 2013; 15 (3): 204-209.

  7. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996; 10 (13): 1580-1594.

  8. Massagué J. TGFβ signaling: receptors, transducers, and mad proteins. Cell. 1996; 85 (7): 947-950.

  9. Schliephake H. Bone growth factors in maxillofacial skeletal reconstruction. Int J Oral Maxillofac Surg. 2002; 31: 469-484.

  10. Burkus JK, Gornet MF, Dickman CA, et al. Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages. J Spinal Disord Tech. 2002; 15: 337-349.

  11. Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg. 2001; 83 (suppl 1): 151-158.

  12. Kokorina N, Lewis J, Zakharkin S, Krebsbach P, Nussenbaum B. rhBMP-2 has adverse effects on human oral carcinoma cell lines in vivo. Laryngoscope. 2012; 122 (1): 95-102. doi: 10.1002/lary.22345.

  13. Thawani J, Wang A, Than K, Lin C, La Marca F, Park P. Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery. 2010; 66: 233-246.

  14. Jin H, Pi J, Huang X, Huang F, Shao W, Li S, et al. BMP2 promotes migration and invasion of breast cancer cells via cytoskeletal reorganization and adhesion decrease: an AFM investigation. Appl Microbiol Biotechnol. 2012; 93 (4): 1715-1723.

  15. Liu J, Ben QW, Yao WY, Zhang JJ, Chen DF, He XY, et al. BMP2 induces PANC-1 cell invasion by MMP-2 overexpression through ROS and ERK. Front Biosci (Landmark Ed). 2012; 17: 2541-2549.

  16. Park Y, Kang MH, Seo HY, Park JM, Choi CW, et al. Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression. Med Oncol. 2010; 27: 1192-1199.

  17. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res. 2005; 20: 2189-2199.

  18. Bach DH, Park HJ, Lee SK. The dual role of bone morphogenetic proteins in cancer. Mol Ther Oncolytics. 2017; 8 :1-13.

  19. Carter TG, Brar PS, Tolas A, Beirne OR. Off-label use of recombinant human bone morphogenetic protein-2 (rhBMP-2) for reconstruction of mandibular bone defects in humans. J Oral Maxillofac Surg. 2008; 66 (7): 1417-1425.

  20. Raida M, Clement JH, Leek RD, Ameri K, Bicknell R, Niederwieser D, et al. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res Clin Oncol. 2005; 131 (11): 741-750.

  21. Clement JH, Raida M, Sanger J, et al. Bone morphogenetic protein 2 (BMP-2) induces in vitro invasion and in vivo hormone dependent growth of breast carcinoma cells. Int J Oncol. 2005; 27: 401-407.

  22. Langenfeld EM, Calvano SE, Abou-Nukta F, et al. The mature bone morphogenetic protein-2 is aberrantly expressed in non–small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis. 2003; 24: 1445-1454.

  23. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004; 2: 141-149.

  24. Kleeff J, Maruyama H, Ishiwata T, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology. 1999; 166: 1202-1216.

  25. Horvath LG, Henshall SM, Kench JG, et al. Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. Prostate. 2004; 59: 234-242.

  26. Sulzbacher I, Birner P, Trieb K, et al. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol. 2002; 55: 381-385.

  27. Orui H, Imaizumi S, Ogino T, et al. Effects of bone morphogenetic protein-2 on human tumor cell growth and differentiation: a preliminary report. J Orthoped Sci. 2000; 5: 600-604.

  28. Asano N, Yamakazi T, Seto M, et al. The expression and prognostic significance of bone morphogenetic protein-2 in patients with malignant fibrous histiocytoma. J Bone Joint Surg Br. 2004; 86: 607-612.

  29. Buckley S, Shi W, Driscoll B, et al. BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol. 2004; 286: L81-L86.

  30. Ro TB, Holt RU, Brenne A, et al. Bone morphogenetic protein-5, -6, and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene. 2003; 23: 3024-3032.

  31. Shepherd TG, Nachtigal MW. Identification of a putative autocrine bone morphogenetic protein signaling pathway in human ovarian surface epithelium and ovarian cancer cells. Endocrinology. 2003; 144: 3306-3314.

  32. Raida M, Sarbia M, Clement JH, et al. Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous cell carcinoma. Int J Cancer. 1999; 83: 38-44.

  33. Ong DB, Colley SM, Norman MR, et al. Transcriptional regulation of a BMP-6 promoter by estrogen receptor alpha. J Bone Miner Res. 2004; 19: 447-454.

  34. Haudenschild DR, Palmer SM, Moseley TA, et al. Bone morphogenetic protein (BMP)–6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res. 2004; 64: 8276-8284.

  35. Masuda H, Fukabori Y, Nakano K, et al. Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate. 2003; 54: 268-274.

  36. Franzen A, Heldin N. BMP-7 induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21 and p27. Biochem Biophys Res Comm. 2001; 285: 773-781.

  37. Yang WH, Lan HY, Tai SK, Yang MH. Repression of bone morphogenetic protein 4 by let-7i attenuates mesenchymal migration of head and neck cancer cells. Biochem Biophys Res Commun. 2013; 433 (1): 24-30.

  38. Jin Y, Tipoe G, Liong E, Lau T, Fun P, Leung K. Overexpression of BMP-2/4, -5 and BMPR-IA associated with malignancy of oral epithelium. Oral Oncology. 2001; 37 (3): 225-233.

  39. Kokorina N, Zakharkin S, Krebsbach P, Nussenbaum B. Treatment effects of rhBMP-2 on invasiveness of oral carcinoma cell lines. Laryngoscope. 2011; 121 (9): 1876-1880. doi: 10.1002/lary.21914.

  40. Kim MJ, Kim KM, Kim J, Kim KN. BMP-2 promotes oral squamous carcinoma cell invasion by inducing CCL5 release. PLoS ONE. 2014; 9 (10): e108170.

  41. Soares A, Xavier R, Miguel M, Souza L, Pinto L. Bone morphogenetic protein-2/4 and bone morphogenetic protein receptor type IA expression in metastatic and nonmetastatic oral squamous cell carcinoma. Am J Otolaryngol. 2010; 31: 266-271.

  42. Xu T, Yu C, Sun J, Liu Y, Wang X, Pi L, et al. Bone morphogenetic protein-4-induced epithelial-mesenchymal transition and invasiveness through Smad1-mediated signal pathway in squamous cell carcinoma of the head and neck. Arch Med Res. 2011; 42: 128-137.

  43. Zhou X, Temam S, Oh M, Pungpravat N, Huang, Mao L, et al. Global expression-based classification of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. Neoplasia. 2006; 8 (11): 925-932.

  44. Sand J, Kokorina N, Zakharkin S, Lewis J, Nussenbaum B. BMP-2 expression correlates with local failure in head and neck squamous cell carcinoma. Otolaryng Head Neck. 2014; 150 (2): 245-250.

  45. Lappin D, Abu-Serriah N, Hunterc K. Effects of recombinant human bone morphogenetic protein 7(rhBMP-7) on the behaviour of oral squamous cellcarcinoma: a preliminary in vitro study. Brit J Oral Max Surg. 2015; 53: 158-163.

  46. Koehler S, Purmessur D, Iatridis J, Hecht A, Qureshi S, Cho S. Does BMP-2 really cause cancer? A systematic review of the literature. Spine J. 2012; 12: 81S-98S. http://dx.doi.org/10.1016/j.spinee.2012.08.252

  47. Skovrlj B, Koehler S, Anderson P, Qureshi S, Hecht A, Iatridis J, et al. Association between BMP-2 and carcinogenicity. Spine. 2015; 40 (23): 1862-1871.

  48. Herford A, Cicciu M. Recombinant human bone morphogenetic protein type 2 jaw reconstruction in patients affected by giant cell tumor. J Craniofac Surg. 2012; 21 (6): 1970-1975.

  49. Wang K, Inman J, Hayden R. Modern concepts in mandibular reconstruction in oral and oropharyngeal cancer. Curr Opin Otolaryngol Head Neck Surg. 2011; 19: 119-124.

  50. Fisher M, Yee K, Alba B, Tanna N, Bastidas N, Bradley J. Applications of bone morphogenetic protein-2: alternative therapies in craniofacial reconstruction. J Craniofac Surg. 2019; 30 (7): 1952-1959.

  51. Paez-Pereda M, Giacomini D, Refojo, D, Nagashima A, Hopfner U, Grubler Y, et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci. 2003; 100: 1034-1039.

  52. Ye L, Kynaston H, Jiang W. Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. J Urol. 2009; 181: 2749-2759.

  53. Cao Y, Slaney C, Bidwell B, Parker B, Johnstone C, Rautela J, et al. BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Res. 2014; 74: 5091-5102.

  54. Woo EJ. Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience database. Spine J. 2012; 12: 894-899.

  55. Jiramongkolchai P, Owens P, Hong CC. Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. Biochem Soc Trans. 2016; 44 (4): 1117-1134.

  56. Ehata S, Yokoyama Y, Takahashi K, Miyazono K. Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde? Pathol Int. 2013; 63 (6): 287-296.

  57. Cooper G, Kou T. Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2). Spine. 2013; 38 (21): 1862-1868.

  58. Davies SD, Ochs MW. Bone morphogenetic proteins in craniomaxillofacial surgery. Oral Maxillofac Surg Clin North Am. 2010; 22 (1): 17-31.




2020     |     www.medigraphic.com